This phase IIb IV-oral step-down study of SCY-078 in patients with in patients with invasive candidiasis
Phase of Trial: Phase II
Latest Information Update: 08 May 2018
At a glance
- Drugs Ibrexafungerp (Primary) ; Ibrexafungerp (Primary)
- Indications Candidiasis
- Focus Therapeutic Use
- 08 May 2018 According to a Scynexis media release, this trial is expected to begin in the fourth quarter of 2018.
- 08 May 2017 According to a Scynexis media release, this trial is expected to begin in 2018.
- 10 Aug 2016 New trial record